Sarcoma Epigenomic Gap Map

Every public epigenomic sample for sarcoma, all ages, at the resolution of one assay on one model in one study. Open data from GEO, controlled-access holdings from EGA and the St Jude Childhood Solid Tumor Network. Click any entity for its full record.

What counts as an entity?

An entity is one diagnostic category in the atlas taxonomy — a WHO 2020 diagnosis, except that rhabdomyosarcoma and liposarcoma are split to molecular subtype (FP-RMS, FN-RMS, MYOD1-mutant; WD/DD/myxoid/pleomorphic/NOS) because that is the resolution the paper argues at. It is the unit each sample is assigned to.

The atlas also carries bins that are not entities, and they are excluded from every count and denominator on this page:

  • Unresolved residual bins — "Sarcoma NOS", "RMS-NOS" and two one-off cases. These hold samples whose diagnosis the deposit never states. They are a measure of metadata quality, not a disease.
  • Control tissue — non-malignant fetal osteoblast, profiled as a reference.

So: . Every "of N" figure on this page uses the named entities only. A sample in a residual bin still appears in the sample and record totals — it exists, we just cannot say what it is.

Open — reusable today Controlled — exists, needs a data-access agreement Methylation only — open, but cannot answer a regulatory question Absent — no record anywhere · Pediatric-predominant Both ages Adult-predominant
Coverage matrix Cell shading is the sample count on a light→dark blue ramp within each column; a red 0 means nothing exists. Sort by clicking a header.
Disease burden against regulatory epigenomics US cases per year (all ages) versus open regulatory samples. Entities on the red floor line have none. Hover a point for detail.
The quilt of unmet need Patch area is how common the disease is; colour is how much of its chromatin anyone has read. A large pale patch is a common sarcoma nobody has profiled. Hover for the numbers, click to open the entity.